Neural Autoantibody Prevalence in New-onset Focal Seizures of Unknown Etiology

Epilepsy Clinical Trial

Official title:

Neural Autoantibody Prevalence in Patients With New-onset Focal Seizures of Unknown Etiology and a Predictive Scoring Scale

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06388161
• Other study ID #: Yan2022-0336
• Status: Recruiting
• Start date: August 1, 2023
• Est. completion date: December 31, 2030

Study information

• Verified date: April 2024
• Source: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Contact: Chun-Hong Shen
• Phone: +86 0571 87783872
• Email: shen_neurology[@]zju.edu.cn
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Seizure is one of the most common symptoms in autoimmune encephalitis with neuronal surface-mediated antibodies. Interestingly, some patients may exhibit new-onset seizures as the initial manifestation without fulminant sign of encephalitis, particularly in the early stage. It is essential to recognize these patients early and to perform antibody testing, as studies have reported early immunotherapy can improve their clinical outcomes. At the same time, it is important to limit the number of patients who require testing, for the sake of specificity and cost effectiveness. Thus, this prospective, multicenter study aims to identify neural antibodies in patients with focal seizures of unknown etiology, and to create a score to preselect patients requiring autoantibody testing.

Description:

1. Focal epileptic seizure or epilepsy is defined according to seizure semiology, electroencephalography findings and/or other relevant information. If applicable, 24 hour video-electroencephalography is performed. 2. Clinical information is documented by specially-assigned persons, including patient demographics, age at onset, disease duration, seizure semiology, seizure frequency, clinical manifestations, underlying malignancy, hyponatremia, brain MRI, medications and other diseases. 3. The Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Hamilton Depression Scale (HAMA), Hamilton Anxiety Scale (HAMA) and the modified Rankin Scale (mRS) at baseline were assessed and recorded. 4. Previous scoring scales, such as antibody prevalence in epilepsy and encephalopathy (APE2) score, antibodies contributing to focal epilepsy signs symptoms (ACES) score and the "Obvious" Indications for Neural Antibody Testing in Epilepsy or Seizures (ONES) checklist are evaluated at baseline. 5. Commercial cell-based assay (CBA; EUROIMMUN, Lübeck, Germany) was used to detect serum anti-N-methyl-D-aspartate receptor (anti-NMDAR), anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (anti-AMPAR), anti-γ-aminobutyric acid B receptor (anti-GABABR), anti-leucine-rich glioma-inactivated 1 (anti-LGI1), anti-contactin-associated protein-like 2 (anti-CASPR2), and anti-glutamic acid decarboxylase 65 (anti-GAD65), anti-metabotropic glutamate receptor 5 (mGluR5), anti-dipeptidyl peptidase-like protein 6 (DPPX), anti-myelin oligodendrocyte glycoprotein (MOG) and anti-immunoglobulin-like cell adhesion molecule 5 (IgLON5) antibodies. If serum neural autoantibodies are detected, cerebrospinal fluid should be tested.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: December 31, 2030
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 14 Years to 100 Years

Eligibility

Inclusion Criteria:

• Patients have a diagnosis of new-onset focal epileptic seizure or epilepsy and present with their first seizure within the previous 12 months
• Patients are prospectively recruited from the routine practice of epileptologists in epilepsy centers and epilepsy clinics
• There is no obvious suspicion of autoimmune encephalitis
• Written informed consent and sera are obtained
• Cerebrospinal fluid test must be conducted, when patients have detectable serum autoantibodies

Exclusion Criteria:

• Patients have other etiology of seizures, such as structure, infection, genetics and metabolism.
• Written informed consent are not obtained
• Loss of follow-up

Related Conditions & MeSH terms

• Encephalitis
• Encephalitis Autoimmune
• Epilepsy
• Seizures

Locations

Country	Name	City	State
China	2nd Affiliated Hospital, School of Medicine, Zhejiang University, China	Hangzhou	Zhejiang

Sponsors (4)

Lead Sponsor	Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University	Ningbo Medical Center Lihuili Hospital, Shaoxing People's Hospital, Sir Run Run Shaw Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Detectable serum neural autoantibodies	such as NMDAR?AMPAR1?AMPAR2?LGI1?lg LON5?DPPX?GAD65?mGluR5?MOG	at baseline
Primary	Neuronal surface antibodies-mediated autoimmune- encephalitis	diagnosed according to the 2016 diagnostic criteria	at baseline
Secondary	The proportion of seizure freedom	We defined seizure freedom according to the International League Against Epilepsy (ILAE) definition	through study completion, an average of 1 year
Secondary	The proportion of drug-resistent epilepsy	We defined drug-resistent epilepsy according to the International League Against Epilepsy (ILAE) definition	through study completion, an average of 1 year
Secondary	Clinical severity and recovery	modified Rankin scale, ranging from 0-6, higher scores mean a worse outcome	through study completion, an average of 1 year